検索ワード: information as part of the clinical trial itself (デンマーク語 - オランダ語)

part of the message
deel van het bericht

part of the swift message
part of the swift message

in any case, only part of the waste paper used to manufacture p&w paper will be paper sold by each beneficiary itself.
in any case, only part of the waste paper used to manufacture p&w paper will be paper sold by each beneficiary itself.

concept paper on the development of a cpmp note for guidance on the clinical pharmacokinetic investigation of the pharmacokinetics of peptides and proteins.
concept paper on the development of a cpmp note for guidance on the clinical pharmacokinetic investigation of the pharmacokinetics of peptides and proteins.

all players which are part of the racing consortium are important constituents of the racing sector.
all players which are part of the racing consortium are important constituents of the racing sector.

the provisions of this annex shall be annexed to , incorporated in and form an integral part of the agreement .
the provisions of this annex shall be annexed to , incorporated in and form an integral part of the agreement .

if fats can be produced automatically as part of an inquiry results process , for example , the costs will be restricted to register and inquiry analysis time .
if fats can be produced automatically as part of an inquiry results process , for example , the costs will be restricted to register and inquiry analysis time .

or ( j ) the assignment of all or a substantial part of the participant 's assets ;
or ( j ) the assignment of all or a substantial part of the participant 's assets ;

such scheme is part of the uk government's integrated approach to tackling the range of regeneration market failures that its most deprived communities face.
such scheme is part of the uk government's integrated approach to tackling the range of regeneration market failures that its most deprived communities face.

concept paper on the development of an appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia
concept paper on the development of an appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia

( 2 ) the following fields of the swift message types shall be checked : details part of the swift message field
( 2 ) the following fields of the swift message types shall be checked : details part of the swift message field

( b ) at all times during the term of this agreement , it will continuously include and maintain as part of its official written books and records this agreement , the netting agreements and evidence of all necessary authorisations .
( b ) at all times during the term of this agreement , it will continuously include and maintain as part of its official written books and records this agreement , the netting agreements and evidence of all necessary authorisations .

and ( b ) at all times during the term of this agreement , it will continuously include and maintain as part of its official written books and records this agreement , the netting agreements and evidence of all necessary authorisations .
and ( b ) at all times during the term of this agreement , it will continuously include and maintain as part of its official written books and records this agreement , the netting agreements and evidence of all necessary authorisations .

substantial parts of the selected investment projects might be essential as well for investment projects in similar production capacity that is not based on using waste p&w paper.
substantial parts of the selected investment projects might be essential as well for investment projects in similar production capacity that is not based on using waste p&w paper.

the executive board of the ecb and the governors of the national central banks shall manage all resources prudently and shall promote effective and cost-efficient solutions in all parts of the eurosystem.
de directie van de ecb en de presidenten van de nationale centrale banken voeren een zorgvuldig beheer van alle middelen en bevorderen doeltreffend en kosteneffectief handelen in alle onderdelen van het eurosysteem.

adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow- acting anti- rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti- fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
adjustment for multiplicity and related topics points to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications: adjustment for baseline covariates points to consider on clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for treatment of dyslipoproteinaemia points to consider on clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections points to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications: